Minodiab (Glipizide)

Glipizide, the active ingredient in Minodiab, is a sulfonylurea presented as an oral tablet for oral use. It stimulates pancreatic beta‑cell insulin release, helping to lower blood glucose levels in adults diagnosed with type 2 diabetes mellitus.

GNH USA supplies Minodiab as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards and regulatory oversight. Our distribution network ensures timely delivery and compliance with local import requirements, supporting consistent patient access to essential antidiabetic therapy.

Glipizide is used to manage hyperglycaemia in type 2 diabetes mellitus, a chronic disorder of glucose metabolism.

- Type 2 diabetes mellitus: Improves glycaemic control when combined with diet and exercise, helping achieve target blood glucose levels. - Adjunct therapy with other oral antidiabetics: Provides additional glucose‑lowering effect in patients not adequately controlled on monotherapy. - Combination with insulin: Allows dose reduction of insulin by enhancing endogenous insulin secretion. - Monotherapy in newly diagnosed patients: Initiates effective glucose control as first‑line oral agent.

Glipizide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypoglycaemia: Low blood sugar episodes, especially if meals are missed or dosing is excessive. - Weight gain: Increase in body weight due to enhanced insulin activity. - Nausea: Mild gastrointestinal discomfort or upset. - Dizziness: Transient light‑headedness or vertigo.

Serious or Rare Side Effects: - Severe hypoglycaemia: Prolonged low glucose requiring medical intervention. - Allergic skin reactions: Rash, pruritus or urticaria indicating hypersensitivity. - Hematologic abnormalities: Neutropenia or agranulocytosis. - Hepatic dysfunction: Elevated liver enzymes or hepatitis.

When prescribing Glipizide, clinicians should consider several safety measures to minimise risk.

- Monitor blood glucose: Adjust dose based on glycaemic response and avoid overt hypoglycaemia. - Assess renal function: Use with caution in patients with impaired kidney function. - Evaluate hepatic status: Reduce dose or avoid in significant liver disease. - Check for sulfonylurea allergy: Discontinue if hypersensitivity signs appear. - Store at ambient temperature below 25°C: Keep in the original pack, protect from moisture.

Glipizide can interact with other medicines, altering its glucose‑lowering effect or increasing adverse event risk.

Major Interactions (Avoid): - Concurrent use with other sulfonylureas: Additive risk of severe hypoglycaemia. - Combination with insulin: May cause profound hypoglycaemia. - Co‑administration with meglitinides: Increases hypoglycaemic potential.

Moderate Interactions (Monitor Closely): - Beta‑blockers: May mask symptoms of hypoglycaemia. - Thiazide diuretics: Can diminish Glipizide’s glucose‑lowering efficacy. - Corticosteroids: May raise blood glucose, reducing therapeutic effect.